IE70732B1 - Tenidap as an inhibitor of the release of elastase by neutrophils - Google Patents

Tenidap as an inhibitor of the release of elastase by neutrophils

Info

Publication number: IE70732B1
Authority: IE; Ireland
Prior art keywords: tenidap; elastase; mammal; salts; neutrophils
Prior art date: 1990-03-19

Application number

IE86191A

Other languages

English (en)

Other versions

IE910861A1 (en

Inventor

Leland David Loose

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-03-19

Filing date

1991-03-15

Publication date

1996-12-11

1991-03-15 Application filed by Pfizer filed Critical Pfizer

1991-09-25 Publication of IE910861A1 publication Critical patent/IE910861A1/en

1996-12-11 Publication of IE70732B1 publication Critical patent/IE70732B1/en

Links

LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 title claims abstract description 36
229960003676 tenidap Drugs 0.000 title claims abstract description 36
102000016387 Pancreatic elastase Human genes 0.000 title claims abstract description 24
108010067372 Pancreatic elastase Proteins 0.000 title claims abstract description 24
210000000440 neutrophil Anatomy 0.000 title abstract description 16
239000003112 inhibitor Substances 0.000 title description 3
150000003839 salts Chemical class 0.000 claims abstract description 37
241000124008 Mammalia Species 0.000 claims abstract description 21
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
230000004064 dysfunction Effects 0.000 claims abstract description 17
230000001404 mediated effect Effects 0.000 claims abstract description 17
201000010099 disease Diseases 0.000 claims abstract description 14
206010014561 Emphysema Diseases 0.000 claims abstract description 6
206010003230 arteritis Diseases 0.000 claims abstract description 6
201000001474 proteinuria Diseases 0.000 claims abstract description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 7
238000007911 parenteral administration Methods 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 5
238000000034 method Methods 0.000 abstract description 11
IGPDWKCUDHIIRL-UHFFFAOYSA-N 5-chloro-2-oxo-3-[oxo(thiophen-2-yl)methyl]-3H-indole-1-carboxamide Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)C1C(=O)C1=CC=CS1 IGPDWKCUDHIIRL-UHFFFAOYSA-N 0.000 abstract 1
239000002585 base Substances 0.000 description 14
150000001875 compounds Chemical class 0.000 description 11
-1 3-substituted-2-oxindole-l-carboxamides Chemical class 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
238000003556 assay Methods 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
239000000243 solution Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methyl-N-phenylamine Natural products CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
229910052784 alkaline earth metal Inorganic materials 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
238000011282 treatment Methods 0.000 description 3
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
102000003820 Lipoxygenases Human genes 0.000 description 2
108090000128 Lipoxygenases Proteins 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
230000003833 cell viability Effects 0.000 description 2
239000006071 cream Substances 0.000 description 2
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000006210 lotion Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
244000182067 Fraxinus ornus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
102100038609 Lactoperoxidase Human genes 0.000 description 1
108010023244 Lactoperoxidase Proteins 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
108010028275 Leukocyte Elastase Proteins 0.000 description 1
102000016799 Leukocyte elastase Human genes 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
102100033174 Neutrophil elastase Human genes 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
241000219061 Rheum Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
229910000102 alkali metal hydride Inorganic materials 0.000 description 1
150000008046 alkali metal hydrides Chemical class 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000004703 alkoxides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
239000010425 asbestos Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000027455 binding Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000004907 flux Effects 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
229940057428 lactoperoxidase Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000003595 mist Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000003961 penetration enhancing agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052573 porcelain Inorganic materials 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
239000000047 product Substances 0.000 description 1
229910052895 riebeckite Inorganic materials 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IE86191A 1990-03-19 1991-03-15 Tenidap as an inhibitor of the release of elastase by neutrophils IE70732B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/495,888 US5006547A (en)	1990-03-19	1990-03-19	Tenidap as an inhibitor of the release of elastase by neutrophils

Publications (2)

Publication Number	Publication Date
IE910861A1 IE910861A1 (en)	1991-09-25
IE70732B1 true IE70732B1 (en)	1996-12-11

Family

ID=23970396

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IE86191A IE70732B1 (en)	1990-03-19	1991-03-15	Tenidap as an inhibitor of the release of elastase by neutrophils

Country Status (17)

Country	Link
US (1)	US5006547A (de)
EP (1)	EP0448261B1 (de)
JP (1)	JPH0678230B2 (de)
KR (1)	KR960016511B1 (de)
AT (1)	ATE133071T1 (de)
AU (1)	AU629109B2 (de)
CA (1)	CA2038410C (de)
DE (1)	DE69116404T2 (de)
DK (1)	DK0448261T3 (de)
HU (1)	HU212492B (de)
IE (1)	IE70732B1 (de)
IL (1)	IL97520A (de)
MY (1)	MY107227A (de)
NZ (1)	NZ237450A (de)
PH (1)	PH27229A (de)
PT (1)	PT97062B (de)
ZA (1)	ZA911980B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5008283A (en) *	1990-03-19	1991-04-16	Pfizer Inc.	Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase
US5122534A (en) *	1991-02-08	1992-06-16	Pfizer Inc.	Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
US5545656A (en) *	1995-04-05	1996-08-13	Pfizer Inc.	2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
US6544556B1 (en)	2000-09-11	2003-04-08	Andrx Corporation	Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
JP2005503772A (ja) *	2001-05-02	2005-02-10	センターフォーブラッドリサーチインコーポレイテッド	エラスターゼインヒビター分泌のモジュレータ
DK2026651T3 (da)	2006-03-08	2013-07-08	Cortria Corp	Kombinationsterapi med ikke-selektive COX-inhibitorer til forebyggelse af COX-relaterede maveskader
EP2886541A1 (de) *	2013-12-19	2015-06-24	Sanofi	Oxindolderivate, ihre Herstellung und ihre therapeutische Verwendung zur Behandlung von durch AMPK vermittelten Erkrankungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4556672A (en) *	1984-03-19	1985-12-03	Pfizer Inc.	3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents
US4678802A (en) *	1985-07-09	1987-07-07	Pfizer Inc.	1-acylcarbamoyloxindole-3-carboxamides as antiinflammatory agents
UA25898A1 (uk) *	1987-02-02	1999-02-26	Пфайзер Інк.	Спосіб одержаhhя кристалічhої hатрієвої солі 5-хлор-3-(2-теhоїл)-2-оксііhдол-1-карбоксаміду
EP0287196B1 (de) *	1987-02-18	1994-11-23	Beecham Group Plc	Indolderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten
US4861794A (en) *	1988-04-13	1989-08-29	Pfizer Inc.	3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis
US4853409A (en) *	1988-04-13	1989-08-01	Pfizer Inc.	3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function
DE3814504A1 (de) *	1988-04-29	1989-11-09	Bayer Ag	(alpha)-substituierte 4-(chinolin-2-yl-methoxy)phenylessigsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln

1990
- 1990-03-19 US US07/495,888 patent/US5006547A/en not_active Expired - Lifetime
1991
- 1991-03-08 DE DE69116404T patent/DE69116404T2/de not_active Expired - Fee Related
- 1991-03-08 EP EP91301963A patent/EP0448261B1/de not_active Expired - Lifetime
- 1991-03-08 AT AT91301963T patent/ATE133071T1/de not_active IP Right Cessation
- 1991-03-08 DK DK91301963.4T patent/DK0448261T3/da active
- 1991-03-08 PH PH42109A patent/PH27229A/en unknown
- 1991-03-12 IL IL9752091A patent/IL97520A/en not_active IP Right Cessation
- 1991-03-15 IE IE86191A patent/IE70732B1/en not_active IP Right Cessation
- 1991-03-15 CA CA002038410A patent/CA2038410C/en not_active Expired - Fee Related
- 1991-03-15 NZ NZ237450A patent/NZ237450A/en unknown
- 1991-03-18 KR KR1019910004237A patent/KR960016511B1/ko not_active Expired - Fee Related
- 1991-03-18 MY MYPI91000439A patent/MY107227A/en unknown
- 1991-03-18 ZA ZA911980A patent/ZA911980B/xx unknown
- 1991-03-18 PT PT97062A patent/PT97062B/pt not_active IP Right Cessation
- 1991-03-18 AU AU73586/91A patent/AU629109B2/en not_active Ceased
- 1991-03-18 HU HU91871A patent/HU212492B/hu not_active IP Right Cessation
- 1991-03-19 JP JP3130751A patent/JPH0678230B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE69116404D1 (de)	1996-02-29
NZ237450A (en)	1997-02-24
EP0448261B1 (de)	1996-01-17
DE69116404T2 (de)	1996-05-30
KR910016327A (ko)	1991-11-05
AU629109B2 (en)	1992-09-24
HUT60622A (en)	1992-10-28
PT97062A (pt)	1991-10-31
HU212492B (en)	1996-07-29
IL97520A0 (en)	1992-06-21
MY107227A (en)	1995-10-31
IE910861A1 (en)	1991-09-25
CA2038410C (en)	1995-01-24
AU7358691A (en)	1992-08-06
EP0448261A3 (en)	1992-04-08
PH27229A (en)	1993-05-04
JPH04234814A (ja)	1992-08-24
ATE133071T1 (de)	1996-02-15
KR960016511B1 (ko)	1996-12-14
IL97520A (en)	1995-12-31
US5006547A (en)	1991-04-09
DK0448261T3 (da)	1996-02-12
PT97062B (pt)	1998-07-31
JPH0678230B2 (ja)	1994-10-05
HU910871D0 (en)	1991-09-30
ZA911980B (en)	1992-10-28
EP0448261A2 (de)	1991-09-25

Legal Events

Date	Code	Title	Description
2001-02-07	MM4A	Patent lapsed

Publication	Publication Date	Title
EP0448261B1 (de)	1996-01-17	Tenidap als Hemmstoff der Elastinfreisetzung durch Neutrophile
EP0337628B1 (de)	1993-05-26	3-Substituierte 2-Oxindol-1-carboxamid-Derivate zur Hemmung der Aktivität der T-Zellen
US5008283A (en)	1991-04-16	Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase
EP0337627B1 (de)	1993-05-26	3-Substituierte 2-Oxindol-1-carboxamid-Derivate als Hemmer der Biosynthese des Interleukins-1
CA2060789C (en)	1995-10-17	Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
EP0841913B1 (de)	2003-02-05	Verwendung von sulfaminsäuren derivaten, acrylsulfonamiden oder sulfonylcarbonaten zur herstellung eines arzneimittels zur senkung des spiegels von lipoproteinen
WO1992003130A1 (en)	1992-03-05	Use of aryl hydroxyurea compounds for the treatment of atherosclerosis
US5192790A (en)	1993-03-09	3-substituted-2-oxindole derivatives as inhibitors of interleukin-1 biosynthesis
JP2690768B2 (ja)	1997-12-17	肝線維化抑制剤
FR2649320A1 (fr)	1991-01-11	Nouvelle association medicamenteuse
YU490A (sh)	1992-12-21	Derivati benzopirana
TH8676B (th)	1998-12-23	องค์ประกอบทางเภสัชที่ใช้ในการรักษาโรคต้อหิน
HUT73810A (en)	1996-09-30	3-substituted-2-oxindoles as inhibitors of viral replication